Company: CNTB
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001835268-25-000014
Chunk: 84

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-03-31
Form: 10-K
Item: Item 16
Chunk 84
---
ITEM 16.       FORM 10-K SUMMARY.

None.

157

TABLE OF CONTENTS

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CONNECT BIOPHARMA HOLDINGS LIMITEDDATE: March 31, 2025BY:/s/ BARRY D. QUARTBarry D. Quart, Pharm.D.Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS that each individual whose signature appears below constitutes and appoints Barry D. Quart as his or her true and lawful attorney-in-fact and agent, with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, with respect to this annual report and any and all amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all the said attorney-in-fact and agent or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

SignatureTitleDate/s/ BARRY D. QUARTChief Executive Officer and DirectorMarch 31, 2025Barry D. Quart, Pharm.D.(Principal Executive Officer)/s/ LISA PERAZAVice President, FinanceMarch 31, 2025Lisa Peraza, CPA(Principal Financial and Accounting Officer)/s/ KLEANTHIS G. XANTHOPOULOSChairman of the Board of DirectorsMarch 31, 2025Kleanthis G. Xanthopoulos, Ph.D./s/ KAN CHENDirectorMarch 31, 2025Kan Chen, Ph.D./s/ JAMES Z. HUANG DirectorMarch 31, 2025James Z. Huang, MBA/s